Screener
R&D at other companies
Other financials
Where this comes from
Reported directly by Rigel Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.
The source filing: Rigel Pharmaceuticals’s 10-Q, filed May 5, 2026.
- Filed
- May 5, 2026, 4:05 PM EDT
- Fiscal quarter
- Q4 FY2026
- Calendar quarter
- Q4 2026
- Accession
- 0001034842-26-000032
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Total revenues | 58,818 | 53,333 |
| Costs and expenses: | ||
| Cost of product sales | 4,606 | 4,409 |
| Research and development | 11,676 | 8,436 |
| Selling, general and administrative | 30,651 | 27,715 |
| Total costs and expenses | 46,933 | 40,560 |
| Income from operations | 11,885 | 12,773 |
| Interest income | 1,205 | 591 |
Item 1. Financial Statements
FAQ
- What is Rigel Pharmaceuticals's R&D?
- Rigel Pharmaceuticals (RIGL) reported R&D of $11.68M in Q1 2026.
- How has Rigel Pharmaceuticals's R&D changed year-over-year?
- Rigel Pharmaceuticals's R&D increased by 38.4% year-over-year, from $8.44M to $11.68M.
- What is the long-term trend for Rigel Pharmaceuticals's R&D?
- Over 4 years (2021 to 2025), Rigel Pharmaceuticals's R&D has grown at a -15.5% compound annual growth rate (CAGR), from $65.24M to $33.3M.
- What does R&D mean?
- Costs of research activities to discover new knowledge and development activities to translate research into new or improved products, services, processes, or technologies.
Ask your AI about Rigel Pharmaceuticals's r&d.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude